Systemic lupus erythematosus disease activity index 2000 responder index-50 enhances the ability of SLE responder index to identify responders in clinical trials

Journal of Rheumatology

Volumn 38, Issue 11, 2011, Pages 2395-2399

  Touma, Zahi ^a   Gladman, Dafna D ^a,b,c   Ibañez, Dominique ^a   Taghavi Zadeh, Shahrzad ^a   Urowitz, Murray B ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Disease activity; Outcome measures; SRI 50; Systemic lupus erythematosus; Systemic lupus erythematosus disease activity index 2000; Systemic lupus erythematosus responder index

Indexed keywords

ADULT; ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX 2000 RESPONDER INDEX 50; SYSTEMIC LUPUS ERYTHEMATOSUS RESPONDER INDEX;

ADULT; ANTIBODIES, MONOCLONAL; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 80155168887     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110550     Document Type: Article

References (17)

1. Touma Z, Urowitz MB, Ibañez D, Gladman DD. SLEDAI-2K Responder Index 50 (SRI-50) [abstract]. Arthritis Rheum 2009;60 Suppl:S899.
2. Touma Z, Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2 (SLEDAI-2K) Responder Index (SRI-50): A valid index for measuring improvement in disease activity [abstract]. Arthritis Rheum 2010;62 Suppl:S785.
3. Touma Z, Gladman DD, Ibanez D, Urowitz MB. Development and initial validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50. J Rheumatol 2011;38:275-84.
4. Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus 2010;19:49-51.
5. Gladman DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29:288-91. (Pubitemid 34118775)
6. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
7. Touma Z, Urowitz MB, Fortin PR, Landolt C, Toloza SM, Riddell C, et al. SLEDAI-2K Responder Index (SRI)-50: A reliable index for measuring improvement in disease activity. J Rheumatol 2011;38:868-73.
8. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
9. Chatham W, Furie R, Petri M, Ginzler EM, Wallace DJ, Stohl W, et al. Belimumab (fully human monoclonal antibody to BLys) improved or stabilized systemic lupus erythematosus (SLE) disease activity over 3 years of therapy [abstract]. Arthritis Rheum 2008;58 Suppl:S1094.
10. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8. (Pubitemid 41785892)
11. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58. (Pubitemid 23223653)
12. Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996;55:756-60. (Pubitemid 26354438)
13. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
15. Touma Z, Urowitz MB, Ibanez D, Gladman DD. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus 2011;20:67-70.
16. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology 2005;44:902-6. (Pubitemid 41511186)
17. Isenberg DA, Gordon C. From BILAG to BLIPS - disease activity assessment in lupus past, present and future. Lupus 2000;9:651-4. (Pubitemid 32011789)